Brief: Ac Immune Reports Positive Safety & Immunogenicity At Week-100 In Part 1 Of Vacsyn Phase 2 Trial Of Aci-7104
23/09/2026 12:01
BRIEF-Ac Immune Reports Positive Safety & Immunogenicity At Week-100 In Part 1 Of Vacsyn Phase 2 Trial Of Aci-7104 AC Immune AG ACIU.O:
AC IMMUNE REPORTS POSITIVE SAFETY & IMMUNOGENICITY AT WEEK-100 IN PART 1 OF VACSYN PHASE 2 TRIAL OF ACI-7104
AC IMMUNE AG - ALL PRIMARY ENDPOINTS MET IN PART 1 OF VACSYN PHASE 2 TRIAL FOR ACI-7104
AC IMMUNE AG - DISCUSSIONS WITH FDA REGARDING ACI-7104 DEVELOPMENT PATH PLANNED FOR EARLY 2027
Source text: ID:nGNX52qtkv
Further company coverage: ACIU.O
Recent news on AC Immune AG
See all newsAC Immune rises after Parkinson's drug shows promise in mid-stage trial
Brief: Ac Immune Reports Positive Safety & Immunogenicity At Week-100 In Part 1 Of Vacsyn Phase 2 Trial Of Aci-7104
U.S. STOCKS ON THE MOVEX-Abbott, Columbia Financial, Jabil
U.S. STOCKS ON THE MOVEX-Abbott, Columbia Financial, Jabil,
U.S. STOCKS ON THE MOVE-Duke Energy, Sea, Cardinal Health